Unknown

Dataset Information

0

A surrogate cell-based SARS-CoV-2 spike blocking assay.


ABSTRACT: To monitor infection by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and successful vaccination against coronavirus disease 2019 (COVID-19), the kinetics of neutralizing or blocking anti-SARS-CoV-2 antibody titers need to be assessed. Here, we report the development of a quick and inexpensive surrogate SARS-CoV-2 blocking assay (SUBA) using immobilized recombinant human angiotensin-converting enzyme 2 (hACE2) and human cells expressing the native form of surface SARS-CoV-2 spike protein. Spike protein-expressing cells bound to hACE2 in the absence or presence of blocking antibodies were quantified by measuring the optical density of cell-associated crystal violet in a spectrophotometer. The advantages are that SUBA is a fast and inexpensive assay, which does not require biosafety level 2- or 3-approved laboratories. Most importantly, SUBA detects blocking antibodies against the native trimeric cell-bound SARS-CoV-2 spike protein and can be rapidly adjusted to quickly pre-screen already approved therapeutic antibodies or sera from vaccinated individuals for their ACE2 blocking activities against any emerging SARS-CoV-2 variants.

SUBMITTER: Schuh W 

PROVIDER: S-EPMC8646767 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC7566699 | biostudies-literature
| S-EPMC8870830 | biostudies-literature
| S-EPMC8856731 | biostudies-literature
| EMPIAR-10947 | biostudies-other
| S-EPMC8673933 | biostudies-literature
| S-EPMC8451402 | biostudies-literature
2023-08-31 | E-MTAB-13040 | biostudies-arrayexpress
| S-EPMC7523104 | biostudies-literature
| EMPIAR-10891 | biostudies-other
| EMPIAR-11038 | biostudies-other